Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed that on 21 May 2026 it bought back 62,000 H shares on the Hong Kong Stock Exchange, paying between HKD 3.50 and HKD 3.51 per share. The aggregate consideration amounted to HKD 217,400 (approximately 0.22 million).

Following the transaction, the company’s outstanding issued share capital (excluding treasury shares) declined by 62,000 shares, or 0.0014%, to 4.47 billion. Treasury shares increased correspondingly from 56.21 million to 56.28 million, leaving total issued shares unchanged at 4.52 billion.

The buy-back forms part of the mandate approved by shareholders on 27 May 2025, which authorises the repurchase of up to 451.56 million shares. To date, 49.63 million shares—equivalent to 10.99% of the issued share base at the time of the mandate—have been repurchased under this authority.

In accordance with Main Board Rule 10.06, Weigao Group is subject to a moratorium on issuing new shares or selling treasury shares until 21 June 2026.